Literature DB >> 32484571

Intervertebral disc and endplate cells response to IL-1β inflammatory cell priming and identification of molecular targets of tissue degeneration.

P De Luca, L de Girolamo, D Kouroupis, M Castagnetta, C Perucca Orfei, D Coviello, S Coco, D Correa, M Brayda-Bruno, A Colombini1.   

Abstract

Inflammation represents an important factor leading to metabolic imbalance within the intervertebral disc (IVD), conducive to degenerative changes. Therefore, a thorough knowledge of the IVD and endplate (EP) cell behaviour in such pathological environments is essential when designing regenerative therapeutic strategies. The present study aimed at assessing the molecular response of the IVD constitutive nucleus pulposus (NPCs)-, annulus fibrosus (AFCs)- and endplate (EPCs)-derived cells to interleukin (IL)-1β treatment, through large-scale, high-throughput microarray and protein analysis, identifying the differentially expressed genes and released proteins. Overall, the inflammatory stimulus downregulated stemness genes while upregulating pro-inflammatory, pro-angiogenic and catabolic genes, including matrix metalloproteases, which were not balanced by a concomitant upregulation of their inhibitors. Upregulation of anti-inflammatory and anabolic tumour necrosis factor inducible gene 6 protein (TNFAIP6), of IL-1 receptor antagonist (IL-1Ra) (at gene and protein levels) and of trophic insulin-like growth factor 1 (IGF1) was also observed in all cell types; IGF1 particularly in AFCs. An overall inhibitory effect of tumour necrosis factor alpha (TNFα) signal was observed in all cell types; however, EPCs showed the strongest anti-inflammatory behaviour. AFCs and EPCs shared the ability to limit the activation of the signalling mediated by specific chemokines. AFCs showed a slightly senescent attitude, with a downregulation of genes related to DNA repair or pro-mitosis. Results allowed for the identification of specific molecular targets in IVD and EP cells that respond to an inflammatory environment. Such targets can be either silenced (when pathological targets) or stimulated to counteract the inflammation.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32484571     DOI: 10.22203/eCM.v039a15

Source DB:  PubMed          Journal:  Eur Cell Mater        ISSN: 1473-2262            Impact factor:   3.942


  5 in total

Review 1.  Gut-disc axis: A cause of intervertebral disc degeneration and low back pain?

Authors:  Wentian Li; Kaitao Lai; Neha Chopra; Zhaomin Zheng; Abhirup Das; Ashish D Diwan
Journal:  Eur Spine J       Date:  2022-03-14       Impact factor: 3.134

2.  Pro-Inflammatory and Neurotrophic Factor Responses of Cells Derived from Degenerative Human Intervertebral Discs to the Opportunistic Pathogen Cutibacterium acnes.

Authors:  Manu N Capoor; Anna Konieczna; Andrew McDowell; Filip Ruzicka; Martin Smrcka; Radim Jancalek; Karel Maca; Michael Lujc; Fahad S Ahmed; Christof Birkenmaier; Stefan Dudli; Ondrej Slaby
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

Review 3.  Should Degenerated Intervertebral Discs of Patients with Modic Type 1 Changes Be Treated with Mesenchymal Stem Cells?

Authors:  Nick Herger; Paola Bermudez-Lekerika; Mazda Farshad; Christoph E Albers; Oliver Distler; Benjamin Gantenbein; Stefan Dudli
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

4.  Intervertebral disc cell chondroptosis elicits neutrophil response in Staphylococcus aureus spondylodiscitis.

Authors:  Tiziano A Schweizer; Federica Andreoni; Claudio Acevedo; Thomas C Scheier; Irina Heggli; Ewerton Marques Maggio; Nadia Eberhard; Silvio D Brugger; Stefan Dudli; Annelies S Zinkernagel
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

5.  Scutellarin Protects Against Mitochondrial Reactive Oxygen Species-Dependent NLRP3 Inflammasome Activation to Attenuate Intervertebral Disc Degeneration.

Authors:  Zihao Wang; Pengfei Zhang; Yunpeng Zhao; Feiran Yu; Shaoyi Wang; Kaiwen Liu; Xiang Cheng; Jie Shi; Qiting He; Yanni Xia; Lei Cheng
Journal:  Front Bioeng Biotechnol       Date:  2022-08-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.